Navigation Links
St. Jude Children's Research Hospital Discovery Aided Quest for Adult Cancer Drug
Date:9/29/2011

l trial of Xalkori to include patients with ALK-positive advanced NSCLC. Xalkori blocks the cancer-causing activity of the ALK protein. Additional clinical trials with the drug are now underway in other cancers, including neuroblastoma and ALCL, the lymphoma that launched the search.

The ALK discovery and related later research led to five U.S. patents for St. Jude. The patented work includes methods for detecting the chromosomal rearrangements that unleash the cancer-causing ability of the ALK gene as well as tools to identify and characterize drugs for cancers caused by ALK deregulation. Morris, Look and their colleagues also worked with another pharmaceutical company to design a diagnostic assay to identify patients with the ALK mutation. The test, a fluorescence in situ hybridization (FISH) assay, has been marketed for more than a decade. In August, it won FDA approval as a diagnostic test for use with Xalkori.

Dr. William E. Evans, St. Jude director and chief executive officer, said the ALK story captures an important aspect of the hospital's commitment. "Our focus is on finding cures for pediatric diseases, but our discoveries often provide insights that can be building blocks for advances in other diseases, including adult cancers. We are committed to facilitating this so that the most good can come from our discoveries," he said.

Working through the St. Jude Office of Technology Licensing, Pfizer obtained licenses to the hospital's patented research tools. Several other companies have executed licenses with St. Jude to use these patent rights.

This year about 210,000 new cases of lung cancer will be diagnosed in the U.S. Current estimates are that approximately 3 to 5 percent, or 6,500 to 11,000 patients with non-small cell lung cancer, carry the ALK rearrangement and may be candidates for treatment with Xalkori.

Today, Morris is a member of the St. Jude Pathology and Oncolo
'/>"/>

SOURCE St. Jude Children's Research Hospital
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
3. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
4. Researchers at Cleveland Clinic Identify Site of Dysfunction in HDL, Carrier of Good Cholesterol
5. Video: New Research Discovers Independent Brain Networks Control Human Walking
6. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
7. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
8. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
9. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
10. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
11. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Feb. 26, 2015  Tandem Diabetes Care®, Inc. (NASDAQ: ... manufacturer of the t:slim® and t:flex™ Insulin Pumps, today ... 5,250,000 shares of its common stock at a price ... proceeds to Tandem from this offering are expected to ... and other estimated offering expenses payable by Tandem. All ...
(Date:2/26/2015)... MOUNTAIN VIEW, Calif. , Feb. 26, 2015  IRIDEX ... will release its fourth quarter and full year 2014 financial ... 2015.   In conjunction with the release, the Company will ... 5:00 p.m. Eastern Time on Thursday, March 5, ... other business developments. Interested parties may access the ...
(Date:2/26/2015)... -- Legislation passed today by the House Ways and ... inappropriate prescriptions in Medicare Part D from crossing the ... Act (PIMA) of 2014 , introduced by Ways and ... and Ranking Member Jim McDermott (D-WA), recognizes the need ... the right policies, said the Pharmaceutical Care Management Association ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 2Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 3IRIDEX Announces Fourth Quarter and Full Year 2014 Conference Call and Release Date 2PCMA Statement on the 'Protecting the Integrity of Medicare Act' 2
... on efforts to enhance the,clinical research enterprise, ... of,Clinical Research Organizations (ACRO), which represents the ... the public in the U.S. and worldwide, ... formed Clinical Trial Transformation,Initiative (CTTI). The goal ...
... for the Treatment of Fever ... Achieves Primary Endpoint ... SAN DIEGO, May 6 Cadence Pharmaceuticals,Inc. (Nasdaq: ... proprietary product candidates principally,for use in the hospital setting, today ...
Cached Medicine Technology:Association of Clinical Research Organizations (ACRO) to Help Lead Clinical Trials Transformation Initiative 2Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update 2Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update 3Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update 4Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update 5Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update 6Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update 7Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update 8Cadence Pharmaceuticals Reports First Quarter 2008 Financial Results and Provides Clinical Program Update 9
(Date:2/28/2015)... (PRWEB) February 28, 2015 Javon ... recognizes Mercy Harvard Hospital as stroke capable by the ... brought via ambulance to Mercy Harvard Hospital. , The ... to indicate their ability to treat stroke according to ... allows ambulances transporting stroke patients to bypass hospitals not ...
(Date:2/28/2015)... FL (PRWEB) February 28, 2015 The ... training and learning materials to potential EMTs and firefighters, ... for Bitcoins as a way to raise charitable donations ... ends in Medellin, Columbia, will be held on March ... the run will begin at 3:30 p.m. , ...
(Date:2/27/2015)... 27, 2015 Wireless Analytics, ... and one of the founders of the ... Bell Mobility within their CLEAN Platform™ (Communications Lifecycle ... Wireless Analytics’ newly developed Bell Mobility Data Loader ... Canadian wireless carrier’s business customers. , Wireless Analytics ...
(Date:2/27/2015)... Those who self-injure, commonly ... misdiagnosed and therefore aren’t receiving effective treatment ... Jacksonville-based addiction treatment center Lakeview Health has ... Lakeview Professional Lecture Series to counselors, physicians, ... complicated condition. , “Self-injurious behaviors ...
(Date:2/27/2015)... Altec Products, Inc., announced today that ... as their doc-link for Dynamics Partner of the Year. ... solutions for their customers in all different industries with ... and BPW have worked side-by-side to successfully help clients ... , “We are so impressed by the success that ...
Breaking Medicine News(10 mins):Health News:Mercy Harvard Hospital Recognized as Leader in Stroke Care - Javon Bea 2Health News:Bitcoin Run Is The World Scout League Commission’s Newest Project for Charity 2Health News:Bell Mobility Gains Traction With Enterprises; Is Added to Wireless Analytics’ CLEAN Platform™ 2Health News:Bell Mobility Gains Traction With Enterprises; Is Added to Wireless Analytics’ CLEAN Platform™ 3Health News:Lakeview Health to Host Important Workshop Tackling the Rising Issue of ‘Cutters’ on March 27 2Health News:Altec Announces 2014 doc-link for Dynamics Partner of the Year Award Recipient 2Health News:Altec Announces 2014 doc-link for Dynamics Partner of the Year Award Recipient 3
... achieve statistical significance, - GPC Biotech schedules conference call for Wednesday, ... ... BOULDER, Colo., MARTINSRIED, Germany, MUNICH, Germany and PRINCETON,N.J., Oct. 30 ... Stock Exchange: GPC; TecDAX index; Nasdaq:,GPCB) today announced topline overall survival ...
... The largest and most up-to-date study of suicides ... help guide screening and treatment for all veterans. ... that the predictors of suicide among veterans in depression ... population, with younger, white, non-Hispanic men having the highest ...
... and OMX Nordic Exchange: EPCT) today announced that Jack ... BioFin Rodman & Renshaw,9th Annual Healthcare Conference on November ... York Palace Hotel in New York. Mr. Talley will ... The presentation will be available live via webcast ...
... ANNAPOLIS, Md., Oct. 30 PharmAthene, Inc., a ... of,medical countermeasures against chemical and biological terrorism,announced today ... Rodman & Renshaw /,Acumen BioFin 9th Annual Healthcare ... local time. Presenting for the Company will be ...
... with a derivative of vitamin A called retinoic acid was ... former heavy smokers, according to a study published online October ... . , Former smokers remain at elevated risk for ... damaged during years of smoking may continue to grow and ...
... York City Marathon 2007 and be Recognized for ... Road Runners and Avis, NEW YORK, Oct. 30 ... announced today that Vincent Corso and Daniel Trush have,won the ... New York City Marathon 2007. The award celebrates people who ...
Cached Medicine News:Health News:Pharmion and GPC Biotech Announce Results of Overall Survival Analysis From the Satraplatin Pivotal Phase 3 Trial 2Health News:Pharmion and GPC Biotech Announce Results of Overall Survival Analysis From the Satraplatin Pivotal Phase 3 Trial 3Health News:Pharmion and GPC Biotech Announce Results of Overall Survival Analysis From the Satraplatin Pivotal Phase 3 Trial 4Health News:Key findings for all veterans seen in depression and suicide study 2Health News:Key findings for all veterans seen in depression and suicide study 3Health News:Key findings for all veterans seen in depression and suicide study 4Health News:EpiCept Corporation To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 2Health News:EpiCept Corporation To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 3Health News:Vitamin A derivative associated with reduced growth in some lung cells 2Health News:Vincent Corso and Daniel Trush Win 2007 Avis 'We Try Harder' Awards 2Health News:Vincent Corso and Daniel Trush Win 2007 Avis 'We Try Harder' Awards 3
VG2 PLIF (Parallel) Posterior lumbar interbody fusion. Frozen preservation. Consists of two outer cortical planks, center cancellous plank, all from the same donor, held together by two press-fit cor...
Allograft implants can be easily used to repair and promote the healing of a wide variety of bone and other tissue defects....
The Natural Selection family of specialty allografts are spinal allograft devices to eliminate the need for painful autograft harvesting....
... comprised of two cortical planks of ... cortical planks provide strength for anterior ... a lattice for remodeling, ensuring an ... surface teeth increase the stability of ...
Medicine Products: